You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.
Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
The INFORM study echoed the 2019 interim results from the NCI Pediatric MATCH trial, which found that 24 percent of participants were eligible for targeted treatment.